Skip to main content
AVIR
NASDAQ Life Sciences

Atea 10-Q: $110.5M Nine-Month Loss, $191.2M Cash, and a New CAO Resignation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.41
Mkt Cap
$353.703M
52W Low
$2.87
52W High
$6.45
52W Position info
54% above low
Off High info
32% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

AVIR sits 54% above its 52-week low of $2.87.

Summary

Atea's Q3 10-Q confirms a $32.2 million quarterly loss and $191.2 million in cash, with the Hercules draw extending runway into mid-2028, and discloses the resignation of its chief accounting officer effective November 13, 2026.


Key Events · Earnings and Guidance · AVIR

  • Q3 Loss Narrows Year Over Year

    Net loss was $32.2 million, or $0.40 per share, versus $42.0 million a year earlier, as R&D fell to $27.1 million from $38.3 million.

  • Cash Down to $191.2 Million

    Cash, equivalents and marketable securities fell from $301.8 million at December 31, 2025 to $191.2 million at September 30, 2026; nine-month operating cash burn was $112.3 million.

  • Hercules Facility Extends Runway

    The up-to-$200 million Hercules loan closed November 6, 2026 with $65.0 million drawn; $30.0 million is at lender discretion and $105.0 million on milestones, at a 9.35% floor with interest-only payments for 48 months.

  • Chief Accounting Officer Resigns

    Wayne Foster, EVP and Chief Accounting Officer, resigned effective November 13, 2026 and will consult through February 2027 to ease the transition.


Analysis · AVIR · Life Sciences

The quarterly report confirms the numbers already released this morning — a $32.2 million Q3 net loss and $191.2 million in cash and investments — but it also carries a fresh governance item: Executive Vice President and Chief Accounting Officer Wayne Foster resigned effective November 13, 2026, staying on as a consultant through February 2027. With the $65.0 million drawn from the Hercules facility, management says funding now runs into mid-2028, past the C-FORWARD Phase 3 readout expected in the first quarter of 2027 and the targeted second-quarter 2027 NDA submission. The accounting officer's exit is a modest negative for a company whose near-term story rests entirely on that trial result.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVIR was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $353.7M. The 52-week trading range was $2.87 to $6.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVIR - Latest Insights

AVIR
Nov 09, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $4.49 info
Change: +$0.0801 (+2%) info
Market Cap: $353.703M info
AVIR
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.39
Real-time Price: $4.49 info
Change: +$0.1001 (+2%) info
Market Cap: $353.703M info
AVIR
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.06
Real-time Price: $4.49 info
Change: -$0.5699 (-11%) info
Market Cap: $353.703M info
AVIR
Jul 28, 2026, 7:41 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.87
Real-time Price: $4.49 info
Change: -$0.3799 (-8%) info
Market Cap: $353.703M info
AVIR
Jul 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.49 info
Change: -$0.2619 (-6%) info
Market Cap: $353.703M info